Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 (CN201) in Precursor B-cell Acute Lymphoblastic Leukemia
NCT05579132Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2022
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CN201 in B-cell acute lymphoblastic leukemia (B-ALL) (2 cohorts), sponsored by Merck & Co. Primary endpoints: Number of Participants who Experience at Least One Adverse Event at 24 months, Number of Participants who Discontinue Study Treatment Due to an AE at 24 months and 3 more. Started Nov 2022; status: recruiting.
02
Drugs
CN201
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05579132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579132.